WQWei Quan

Wei Quan

*This is an algorithmically generated author record based on publicly available information.

Wei Quan has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Identifying Key Plasma Proteins in the Onset of Parkinson’s Disease: Proteome-Wide Mendelian Randomization and Single-Cell RNA Sequencing Analysis

    by Wei Quan, Lin Wang, Jing Xu, Jia Song, Yidan Qin, Huibin Zeng, Jia Li, Jiajun Chen

    Currently, the pathogenesis of Parkinson’s disease (PD) remains enigmatic, primarily due to the scarcity of definitive diagnostic markers, thereby hampering both diagnosis and treatment. The urgent need for accessible plasma markers and targeted therapeutic agents has prompted us to employ various methodologies. We leveraged Mendelian randomization analysis, colocalization analysis, SMR analysis, and the HEIDI test to delve into the causal relationships between 2923 plasma proteins in the UK Biobank and PD. Our findings revealed that 21 plasma proteins, including CTF1 and STX4, may demonstrate causal relationships with PD. Further single-cell and bioinformatics analyses have shed light on the fact that 18 of these proteins exhibit differential expression across various brain cell types in patients with PD. These proteins are involved in crucial biological processes, including peptide binding, amide binding, amyloid-beta binding, endocytic vesicle formation, and the functioning of early endosomes. Notably, the PPI network exhibited interactions between ITGAM and HLA-DRA, as well as APOE, while APOE displayed interactions with APOA1, and SERPINE2 interacted with VNN2. Furthermore, our study demonstrates that plasma proteins, including CTF1, STX4, HPGDS, and APOA1, exhibit therapeutic potential for drug development based on gene-drug interaction predictions. While these findings provide a theoretical basis for the exploration of diagnostic markers and potential therapeutic targets for PD, extensive experimental validation is essential to confirm their potential in the future.


  • Causal role of myeloid cells in Parkinson’s disease: Mendelian randomization study

    by Wei Quan, Yidan Qin, Jia Li, Lin Wang, Jia Song, Jing Xu, Jiajun Chen

    Background Previous studies have observed elevated myeloid cells in the peripheral blood of patients with Parkinson's disease (PD), but the causal relationship between them remains to be elucidated. We investigated whether there is a causal relationship between different subtypes of peripheral blood myeloid cells and PD using Mendelian randomization (MR) combined with bioinformatics analysis. Exploring the etiology of PD from the perspective of genetics can remove confounding factors and provide a more reliable theoretical basis for elucidating the pathogenesis of PD. Methods Comprehensive two-sample MR analysis and sensitivity analyses were conducted to explore the causal associations between 64 myeloid cell signatures and PD risk. The Venn diagram and protein-protein interaction network analysis of instrumental variables (IV) corresponding genes were used to further investigate the potential mechanism of myeloid cells influencing the pathogenesis of PD. Results We investigated the impact of four immunophenotypes on the risk of PD, including Im MDSC% CD33dim HLA DR− CD66b− (relative count), CD33dim HLA DR+ CD11b+% CD33dim HLA DR+ (relative count), and CD11b on Mo MDSC (MFI) and CD11b on CD33br HLA DR+ CD14dim (MFI), while an immunophenotype's protective effect on PD was observed CD45 on Im MDSC (MFI). The results of bioinformatics analysis showed that CD33, NTRK2, PLD2, GRIK2 and RELN had protein interactions with the risk genes of PD. Conclusions Our study has demonstrated a close genetic correlation between different subtypes of myeloid cells and PD, providing guidance for early identification and immunotherapeutic development in patients with PD.


  • Investigating the TLR4/TAK1/IRF7 axis in NLRP3-Mediated Pyroptosis in Parkinson's Disease

    by Wei Quan, Ying Liu, Jia Li, Dawei Chen, Jing Xu, Jia Song, Jiajun Chen, Shilong Sun

    In the realm of Parkinson's disease (PD) research, NLRP3 inflammasome-mediated pyroptosis has recently garnered significant attention as a potential novel form of dopaminergic neuronal death. Our previous research revealed the activation of innate immune-related genes, such as the TLR4 signaling pathway and interferon regulatory factor 7 (IRF7), although the specific mechanism remains unclear. Our current study shed light on whether the TLR4 signaling pathway and IRF7 can affect the pyroptosis of dopaminergic nerve cells and thus participate in the pathogenesis of PD. The PD model was constructed by MPP+ treatment of PC12 cells or stereotactic injection of the striatum of SD rats, and the expression of genes were detected by RT-qPCR and Western Blotting. Lentivirus, siRNA and (5Z)-7-Oxozeaenol were used to validate the regulation of this pathway on pyroptosis. The expression of TLR4, TAK1, IRF7 and pyroptosis molecular markers was upregulated after MPP+ treatment. IRF7 could affect dopaminergic neural cells pyroptosis by targeted regulation of NLRP3. Furthermore, inhibition of the TLR4/TAK1 signaling pathway led to a decrease in the expression of both IRF7 and NLRP3, while overexpression of IRF7 reversed the reduction in pyroptosis and increase in TH expression. TLR4/TAK1/IRF7 axis can promote PD by influencing pyroptosis through NLRP3.


  • Open Access

    CD20-positive subcutaneous panniculitis-like T-cell lymphoma presenting as polycranial neuropathy: A CARE-compliant case report and literature review

    by Jing Xu, Jia Li, Ya-Juan Sun, Wei Quan, Li Liu, Qing-Hui Postgraduate Student Zhang, Yi-Dan Postgraduate Student Qin, Xiao-Chen Postgraduate Student Pei, Hang Postgraduate Student Su, Jia-Jun Chen

    Background: Subcutaneous panniculitis-like T-cell lymphoma(SPTCL) is a very rare cytotoxic T-cell skin lymphoma involving subcutaneous tissue, and mainly affects young females. T-cell phenotype is characterized by CD3+, CD8+, and CD4−. SPTCT with polycranial neuropathy has rarely been described. SPTCL is believed to show an indolent clinical course unless patients develop haemophagocytic syndrome or sudden respiratory failure. Its treatment has not been established yet. Case presentation: We report a case of intractable SPTCT in a 66-year-old woman with multiple cranial nerve palsies and diabetes. She showed involvement of the bilateral facial nerve, left trigeminal nerve, left auditory nerve, and right oculomotor nerve. The single inconspicuous skin lesion in the trunk presented with an erythematous nodule with a diameter of <5 cm and a slightly pink infiltrated plaque. Electromyography revealed bilateral damage to the facial nerve. Differential immunohistochemical characteristics were observed. Immunohistochemistry demonstrated diffuse CD20 positivity. Cerebral spinal fluid analysis revealed elevated protein levels of 0.92 (0.15–0.45) g/L. Her condition regressed severely over time. She was treated with chemotherapy but died 10 months later, the probable cause of death was lung involvement. Conclusion: The patient’s involvement with the central nervous system may be associated with positivity for CD20. Molecular biomarkers may act as therapeutic targets for SPTCL.


  • Effect of GBA gene variants on clinical characteristics of dementia with Lewy bodies: a review and meta-analyses

    by Li Liu, Jia Li, Wei Quan, Yidan Qin, Qinghui Zhang, Xiaochen Pei, Hang Su, Jing Xu, Jiajun Chen

    Objectives Glucocerebrosidase (GBA) gene may be a risk factor for dementia with Lewy bodies (DLB). However, due to the small number of existing studies and the small sample size of previous investigations, it is necessary to conduct objective and quantitative analyses of the association between GBA variants and DLB. There is no consensus regarding the relationship between GBA and the clinical characteristics of DLB. Therefore, we conducted multiple systematic reviews and meta-analyses with a particular focus on the age of onset, sex, and cognitive impairment. Methods PubMed, Cochrane, and EMBASE databases were searched to retrieve related studies. The odds ratios and 95% confidence interval were calculated to determine the association between GBA and DLB and between GBA and the clinical characteristics of DLB. Results Our meta-analysis confirmed that the GBA variant rate was significantly higher in the DLB group than in the control group, as were the variant rates of L444P, N370S, and E326K, whereas the variant rate of T369M showed no significant difference between the groups. Furthermore, the relevant literature was summarised again for meta-analyses. The GBA variant group had a younger age of onset and lower Montreal Cognitive Assessment score than the GBA non-variant group in DLB patients. GBA variants do not differ between sexes in DLB patients. Conclusions GBA variants increased the risk of DLB, especially N370S, E326K, and L444P which are strongly associated with DLB, but T369M was not. Patients harbouring GBA variants have an earlier age of onset, more severe cognitive impairment, and rapid symptom progression; however, sex is irrelevant in DLB.


  • Open Access

    Influence of N6-Methyladenosine Modification Gene HNRNPC on Cell Phenotype in Parkinson’s Disease

    by Wei Quan, Jia Li, Li Liu, Qinghui Zhang, Yidan Qin, Xiaochen Pei, Jiajun Chen

    This study aimed to explore the N6-methyladenosine (m6A) modification genes involved in the pathogenesis of Parkinsons disease (PD) through data analysis of the two data sets GSE120306 and GSE22491 in the GEO database and further explore its influence on cell phenotype in PD. We analyzed the differentially expressed genes and function enrichment analysis of the two sets of data and found that the expression of the m6A-modification gene HNRNPC was significantly downregulated in the PD group, and it played an important role in DNA metabolism, RNA metabolism, and RNA processing and may be involved in PD. Then, we constructed the HNRNPC differential expression cell line to study the role of this gene in the pathogenesis of PD. The results showed that overexpression of HNRNPC can promote the proliferation of PC12 cells, inhibit their apoptosis, and inhibit the expression of inflammatory factors IFN-β, IL-6, and TNF-α, suggesting that HNRNPC may cause PD by inhibiting the proliferation of dopaminergic nerve cells, promoting their apoptosis, and causing immune inflammation. Our study also has certain limitations. For example, the data of the experimental group and the validation group come from different cell types, and the data of the experimental group involve individuals with G2019S LRRK2 mutations. In addition, due to the low expression of HNRNPC in PC12 cells, we used the method of overexpressing this gene to study its function. All these factors may cause our conclusions to be biased. Therefore, more research is still needed to corroborate it in the future.


  • Quantitative assessment of the effect of FGF20 rs1721100 and rs12720208 variant on the risk of sporadic Parkinson’s disease: a meta-analysis

    by Wei Quan, Jia Li, Li Liu, Qinghui Zhang, Yidan Qin, Xiaochen Pei, Jiajun Chen

    Objectives While many studies have investigated the associations between fibroblast growth factor 20 (FGF20) rs1721100 (C/G) and rs12720208 (C/T) polymorphisms and susceptibility to Parkinson’s disease (PD), their results are controversial. Our present meta-analysis estimated the overall association between FGF20 rs1721100 and rs12720208 polymorphisms and the risk of sporadic PD. Methods We performed a comprehensive literature search of the PubMed, Web of Science, Embase, Chinese National Knowledge Infrastructure, and Wanfang Medicine electronic databases, which was updated in April 2021. Based on strict inclusion and exclusion criteria, the analysis included a total of 10 papers involving 14 studies with 5262 cases of PD and 6075 controls. Review Manager 5.4 software was used to assess the available data from each study. The pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to assess the association between the FGF20 rs1721100 and rs12720208 polymorphisms and sporadic PD risk. Results Our results showed that the FGF20 rs1721100 G allele frequency and genotype distribution did not differ between PD patients and controls. Similarly, the FGF20 rs12720208 T allele frequency and genotype distribution did not differ significantly between the two groups. A subgroup analysis of Asian and Caucasian populations also showed the same results. Conclusions The results of this meta-analysis indicated that neither the rs1721100 C/G nor the rs12720208 C/T variants were associated with sporadic PD susceptibility.

  • Open Access

    Identification of Potential Core Genes in Parkinson’s Disease Using Bioinformatics Analysis

    by Wei Quan, Jia Li, Xiya Jin, Li Liu, Qinghui Zhang, Yidan Qin, Xiaochen Pei, Jiajun Chen

    Purpose. This study aimed to explore new core genes related to the occurrence of Parkinsons disease (PD) and core genes that can lead to the progression of PD. Methods. The expression profile data of GSE42966, which contained six substantia nigra tissues isolated from normal individuals and nine substantia nigra tissues isolated from patients with PD, were obtained from Gene Expression Omnibus. Differentially expressed genes (DEGs) were identified, followed by functional enrichment analysis and protein-protein interaction (PPI) network construction. We then identified 10 hub genes and analyzed their expression in different Braak stages. Results. A total of 773 DEGs were identified that were significantly enriched in metabolic pathways. Ten hub genes were identified through the PPI network, namely, GNG3, MAPK1, FPR1, ATP5B, GNG2, PRKACA, HRAS, HSPA8, PSAP, and GABBR2. The expression of HRAS was different in patients with PD with Braak stages 3 and 4. Conclusion. These 10 hub genes and the metabolic pathways they are enriched in may be involved in the pathogenesis of PD. HRAS may have potential value in predicting the progression of PD.